-
公开(公告)号:US20070213364A1
公开(公告)日:2007-09-13
申请号:US10594996
申请日:2005-03-28
申请人: Tsuneo Yasuma , Shuji Kitamura , Nozomu Sakai
发明人: Tsuneo Yasuma , Shuji Kitamura , Nozomu Sakai
IPC分类号: A61K31/47 , A61K31/4439 , A61K31/415 , A61K31/404 , A61K31/40 , A61K31/381 , C07D403/02
CPC分类号: A61K31/381 , A61K31/40 , A61K31/402 , A61K31/404 , A61K31/415 , A61K31/4174 , A61K31/4184 , A61K31/4439 , A61K31/445 , A61K31/4453 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/554 , C07D207/325 , C07D209/08 , C07D211/46 , C07D215/06 , C07D231/12 , C07D333/56 , C07D401/12 , C07D403/04 , C07D513/04
摘要: The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
摘要翻译: 本发明旨在提供具有GPR40受体功能调节作用的新化合物,其可用作胰岛素促分泌素,用于预防或治疗糖尿病等的药剂。 由下式表示的化合物:其中每个符号如本说明书中所定义,其盐及其前药意外地具有优异的GPR40受体激动活性和作为稳定性等药物的优异性能, 并且可以是安全有用的药剂作为预防或治疗哺乳动物中GPR40受体相关病理学或疾病的药剂。
-
公开(公告)号:US07517910B2
公开(公告)日:2009-04-14
申请号:US10594996
申请日:2005-03-28
申请人: Tsuneo Yasuma , Shuji Kitamura , Nozomu Sakai
发明人: Tsuneo Yasuma , Shuji Kitamura , Nozomu Sakai
IPC分类号: A61K31/192 , C07C61/12
CPC分类号: A61K31/381 , A61K31/40 , A61K31/402 , A61K31/404 , A61K31/415 , A61K31/4174 , A61K31/4184 , A61K31/4439 , A61K31/445 , A61K31/4453 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/554 , C07D207/325 , C07D209/08 , C07D211/46 , C07D215/06 , C07D231/12 , C07D333/56 , C07D401/12 , C07D403/04 , C07D513/04
摘要: The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
摘要翻译: 本发明旨在提供具有GPR40受体功能调节作用的新化合物,其可用作胰岛素促分泌素,用于预防或治疗糖尿病等的药剂。 由下式表示的化合物:其中每个符号如本说明书中所定义,其盐及其前药意外地具有优异的GPR40受体激动活性和作为稳定性等药物的优异性能, 并且可以是安全有用的药剂作为预防或治疗哺乳动物中GPR40受体相关病理学或疾病的药剂。
-
公开(公告)号:US20070155808A1
公开(公告)日:2007-07-05
申请号:US10584730
申请日:2004-12-24
申请人: Tsuneo Yasuma , Shinobu Sasaki , Nozomu Sakai
发明人: Tsuneo Yasuma , Shinobu Sasaki , Nozomu Sakai
IPC分类号: A61K31/426 , A61K31/421
CPC分类号: C07D277/42 , C07D263/48 , C07D417/04 , C07D417/12
摘要: The present invention provides a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, a drug for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof have unexpectedly superior GPR40 receptor agonist activity and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful drugs for the prophylaxis or treatment of GPR40 receptor related conditions or diseases in mammals.
摘要翻译: 本发明提供具有GPR40受体功能调节作用的新化合物,其可用作胰岛素促分泌素,用于预防或治疗糖尿病等的药物。 由式(I)表示的化合物,其中每个符号如说明书中所定义,其盐和前药具有出人意料的优异的GPR40受体激动剂活性,并且还表现出作为药物的优异性质,例如稳定性等。 因此,它们可以是用于预防或治疗哺乳动物中GPR40受体相关病症或疾病的安全有用的药物。
-
公开(公告)号:US07585880B2
公开(公告)日:2009-09-08
申请号:US10584730
申请日:2004-12-24
申请人: Tsuneo Yasuma , Shinobu Sasaki , Nozomu Sakai
发明人: Tsuneo Yasuma , Shinobu Sasaki , Nozomu Sakai
IPC分类号: A61K31/443 , A61K31/4439 , A61K31/427 , A61K31/422 , C07D277/22 , C07D263/32 , C07D417/10 , C07D413/10
CPC分类号: C07D277/42 , C07D263/48 , C07D417/04 , C07D417/12
摘要: The present invention provides a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, a drug for the prophylaxis or treatment of diabetes and the like.A compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof have unexpectedly superior GPR40 receptor agonist activity and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful drugs for the prophylaxis or treatment of GPR40 receptor related conditions or diseases in mammals.
摘要翻译: 本发明提供具有GPR40受体功能调节作用的新化合物,其可用作胰岛素促分泌素,用于预防或治疗糖尿病等的药物。 由式(I)表示的化合物,其中每个符号如说明书中所定义,其盐和前药具有出人意料的优异的GPR40受体激动剂活性,并且还表现出作为药物的优异性质,例如稳定性等。 因此,它们可以是用于预防或治疗哺乳动物中GPR40受体相关病症或疾病的安全有用的药物。
-
公开(公告)号:US20070149608A1
公开(公告)日:2007-06-28
申请号:US10584481
申请日:2004-12-24
申请人: Tsuneo Yasuma , Shuji Kitamura , Nobuyuki Negoro
发明人: Tsuneo Yasuma , Shuji Kitamura , Nobuyuki Negoro
IPC分类号: A61K31/4015 , A61K31/382 , A61K31/337 , A61K31/34 , A61K31/165 , A61K31/192
CPC分类号: C07D207/08 , C07C59/68 , C07C69/734 , C07C205/34 , C07C217/20 , C07C233/18 , C07C309/66 , C07C317/18 , C07C323/12 , C07C2601/02 , C07D207/27 , C07D213/30 , C07D277/24 , C07D295/088 , C07D295/185 , C07D295/205 , C07D305/06 , C07D309/12 , C07D333/32 , C07D335/02 , C07F9/4006
摘要: The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals.
摘要翻译: 本发明提供由式(I)表示的新化合物,其中每个符号如本说明书中所定义,其具有优异GPR40受体功能调节作用的盐及其前药,其可用作胰岛素促分泌素, 用于预防或治疗糖尿病等的药剂。 它们意外地显示出优异的GPR40受体激动剂活性,并且还表现出作为药物产品的优异性质,例如稳定性等。 因此,它们可以是用于预防或治疗哺乳动物中GPR40受体相关疾病的安全有用的药剂。
-
公开(公告)号:US07456218B2
公开(公告)日:2008-11-25
申请号:US10584481
申请日:2004-12-24
申请人: Tsuneo Yasuma , Shuji Kitamura , Nobuyuki Negoro
发明人: Tsuneo Yasuma , Shuji Kitamura , Nobuyuki Negoro
IPC分类号: A61K31/192 , C07C51/09
CPC分类号: C07D207/08 , C07C59/68 , C07C69/734 , C07C205/34 , C07C217/20 , C07C233/18 , C07C309/66 , C07C317/18 , C07C323/12 , C07C2601/02 , C07D207/27 , C07D213/30 , C07D277/24 , C07D295/088 , C07D295/185 , C07D295/205 , C07D305/06 , C07D309/12 , C07D333/32 , C07D335/02 , C07F9/4006
摘要: The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals.
摘要翻译: 本发明提供由式(I)表示的新化合物,其中每个符号如本说明书中所定义,其具有优异GPR40受体功能调节作用的盐及其前药,其可用作胰岛素促分泌素, 用于预防或治疗糖尿病等的药剂。 它们意外地显示出优异的GPR40受体激动剂活性,并且还表现出作为药物产品的优异性质,例如稳定性等。 因此,它们可以是用于预防或治疗哺乳动物中GPR40受体相关疾病的安全有用的药剂。
-
公开(公告)号:US08318746B2
公开(公告)日:2012-11-27
申请号:US12451130
申请日:2008-04-25
申请人: Tsuneo Yasuma , Kentaro Hashimoto , Masahiro Ito
发明人: Tsuneo Yasuma , Kentaro Hashimoto , Masahiro Ito
IPC分类号: A61K31/496 , A61K31/4427 , A61K31/427 , C07D403/14 , C07D401/14 , C07D277/20
CPC分类号: C07D207/34 , C07D233/64 , C07D233/68 , C07D401/04 , C07D401/14 , C07D405/06 , C07D413/06 , C07D417/04 , C07D417/14
摘要: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention has a glucokinase activity, and is useful as a medicament such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like.
摘要翻译: 本发明提供由式(I)表示的化合物:其中每个符号如说明书中所定义,或其盐。 本发明的化合物具有葡糖激酶活性,可用作糖尿病,肥胖等的预防或治疗药物等药物。
-
公开(公告)号:US20120046338A1
公开(公告)日:2012-02-23
申请号:US13287639
申请日:2011-11-02
IPC分类号: A61K31/382 , C07D307/84 , A61P3/10 , A61K31/343
CPC分类号: C07D409/12 , C07D307/80
摘要: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
摘要翻译: 本发明提供由式(I)表示的化合物:其中每个符号如说明书中所定义,或其盐。 化合物或其盐或其前药具有GPR40受体功能调节作用,并且可用作胰岛素促分泌素或用于预防或治疗糖尿病等的药剂。
-
公开(公告)号:US20110263562A1
公开(公告)日:2011-10-27
申请号:US13094015
申请日:2011-04-26
申请人: Tohru Yamashita , Makoto Kamata , Hideki Hirose , Masataka Murakami , Takuya Fujimoto , Zenichi Ikeda , Tsuneo Yasuma , Ikuo Fujimori , Ryo Mizojiri , Tomoya Yukawa
发明人: Tohru Yamashita , Makoto Kamata , Hideki Hirose , Masataka Murakami , Takuya Fujimoto , Zenichi Ikeda , Tsuneo Yasuma , Ikuo Fujimori , Ryo Mizojiri , Tomoya Yukawa
IPC分类号: A61K31/423 , A61K31/438 , A61K31/439 , C07D417/04 , A61K31/454 , A61K31/416 , A61K31/34 , C07D498/04 , C07D413/14 , C07D413/04 , C07D263/56 , C07D231/56 , C07D307/87 , A61P35/04 , A61P3/04 , A61P3/06 , A61P9/12 , A61P9/00 , A61P3/10 , A61P3/00 , A61K31/497
CPC分类号: C07D413/14 , A61K31/41 , A61K31/415 , A61K31/439 , A61K31/4439 , A61K31/444 , C07D231/54 , C07D263/56 , C07D263/58 , C07D307/81 , C07D401/02 , C07D401/14 , C07D403/02 , C07D405/02 , C07D413/04 , C07D417/04 , C07D487/08 , C07D491/048 , C07D498/04
摘要: The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.
摘要翻译: 本发明提供具有ACC抑制作用的化合物,其可用作预防或治疗肥胖症,糖尿病,高血压,高脂血症,心力衰竭,糖尿病并发症,代谢综合征,肌肉减少症,癌症等的药剂,以及 具有优越的疗效。 本发明涉及由式(I)表示的化合物:其中每个符号如说明书中所定义。
-
公开(公告)号:US20110190335A1
公开(公告)日:2011-08-04
申请号:US12937820
申请日:2009-04-15
申请人: Tsuneo Yasuma , Osamu Ujikawa
发明人: Tsuneo Yasuma , Osamu Ujikawa
IPC分类号: A61K31/437 , C07D277/28 , A61K31/427 , C07D471/02 , C07D401/14 , A61K31/4439 , A61P3/10
CPC分类号: C07D405/14 , C07D417/14 , C07D471/04
摘要: The purpose of the present invention is to provide a glucokinase activator which is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, obesity and the like, and the like.The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
摘要翻译: 本发明的目的是提供可用作药剂的糖激酶活化剂,例如用于预防或治疗糖尿病,肥胖症等的药剂。 本发明是由式(I)表示的化合物:其中各符号如说明书中所定义,或其盐。
-
-
-
-
-
-
-
-
-